FDA Approves 1st Treatment of 8 Weeks Duration for All HCV Genotypes
August 7, 2017
FDA approves Mavyret for Hepatitis C
The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype 1 infection who have been previously treated with a regimen either containing an NS5A inhibitor or an NS3/4A protease inhibitor but not both.
Mavyret is the first treatment of eight weeks duration approved for all HCV genotypes 1-6 in adult patients without cirrhosis who have not been previously treated. Standard treatment length was previously 12 weeks or more.
Continue reading this entire article:
Additional information regarding Mavyret can be found at www.hepatitiscentral.com/mavyret-glecaprevir-pibrentasvir/what-is-mavyret/.
New FDA-Approved Triple-Drug-Regimen for Re-Treatment of Hep C
A New Solution to Relieve Fatigue Caused by Hepatitis C